Latest news with #biomedical
Yahoo
15 hours ago
- Business
- Yahoo
ClavystBio and A*STAR Partner to Grow MedTech Ventures in Singapore
SINGAPORE, June 10, 2025 /PRNewswire/ -- ClavystBio, a life sciences investor and venture builder established by Temasek, and the Agency for Science, Technology and Research (A*STAR), Singapore's lead public sector R&D agency, have signed a Memorandum of Understanding (MoU) to create and grow MedTech ventures in Singapore. This partnership will support venture creation, product development, and commercialisation by bringing together ClavystBio and two national initiatives hosted by A*STAR — MedTech Catapult and the Diagnostics Development Hub (DxD Hub) — along with A*STAR's broader MedTech and venture creation capabilities. The partnership comes amid growing momentum in Singapore's biomedical landscape, with MedTech output reaching S$20 billion in 2023.[1] As Asia's MedTech market is projected to grow to US$225 billion (S$304 billion) by 2030,[2] these efforts aim to better position Singapore-based innovations to scale and enter new markets. Over this two-year partnership, the parties will work towards the co-creation of new MedTech ventures, investments into A*STAR affiliated companies, and fostering collaborations between A*STAR and ClavystBio's portfolio companies. By combining complementary strengths — from research and engineering to venture building and funding — the partnership aims to identify promising technologies, shape MedTech projects for market readiness, and support new venture formation to strengthen Singapore's innovation-driven MedTech ecosystem. The partnership will focus on several key areas: Fostering new ventures from research: A*STAR and ClavystBio will jointly identify promising research and technologies to venture build new MedTech companies. A*STAR will contribute deep scientific expertise and structured venture creation support, while ClavystBio will provide access to venture and growth capital, expert guidance, and its extensive network to launch and scale these early-stage companies. Advancing MedTech product development: MedTech Catapult will support the development of medical devices through engineering design, prototyping, and manufacturing translation, while ClavystBio will draw on its investment and industry relationships to explore potential commercial pathways for promising innovations. Accelerating commercial readiness in diagnostics and digital health: DxD Hub and ClavystBio will shape ventures in this space with strong commercial potential. DxD Hub will bring technical and productisation expertise — including in AI-powered software, multi-omics, and point-of-care diagnostics — to refine innovations for commercial viability. ClavystBio will contribute its venture investing and venture building expertise to drive commercialisation. Strengthening Singapore's MedTech ecosystem: To support long-term sector growth, the partners will assess Singapore's MedTech manufacturing, design, and regulatory support landscape. MedTech Catapult will lead efforts to map ecosystem capabilities and identify gaps, while ClavystBio will explore investment opportunities in companies with specialised technologies that can strengthen Singapore's MedTech value chain. "This partnership highlights ClavystBio's commitment to nurturing globally successful medical devices, digital health, and diagnostics companies from Singapore," said Mr Anselm Tan, Digital Health & MedTech Lead at ClavystBio. "By combining ClavystBio's investment and venture-building expertise with A*STAR's deep scientific capabilities and productisation platforms, we are cultivating an ecosystem primed for innovation and commercial success. "A*STAR is committed to nurturing a dynamic MedTech ecosystem that bridges innovation with deep tech companies," said Ms Irene Cheong, Assistant Chief Executive (Innovation & Enterprise) at A*STAR. "This MoU builds on an existing collaboration with ClavystBio and marks a significant step forward in our joint efforts to co-create and grow globally investible MedTech ventures. Through national productisation platforms like MedTech Catapult and DxD Hub, combined with A*STAR's venture creation capabilities, we aim to commercialise more innovations from lab to market and grow a vibrant MedTech ecosystem in Singapore." [1] Speech by SMS Low Yen Ling at the MedTech Forum[2] Singapore's MedTech sector and locally made medical devices punching above their weight | Singapore EDB About ClavystBio ClavystBio is a life sciences investor and venture builder set up by Temasek to accelerate the commercialization of breakthrough ideas into health impact. We invest and partner with founders and entrepreneurs to launch and grow global companies from Singapore. Our focus spans therapeutics, digital health and medtech, with an emphasis on first-in-class science and technology. Our collaborative space, Node 1, provides plug-and-play spaces for ventures that have graduated from incubators to progress to their next milestones. By bringing start-ups together, we foster a vibrant and supportive community. About the Agency for Science, Technology and Research (A*STAR) The Agency for Science, Technology and Research (A*STAR) is Singapore's lead public sector R&D agency. Through open innovation, we collaborate with our partners in both the public and private sectors to benefit the economy and society. As a Science and Technology Organisation, A*STAR bridges the gap between academia and industry. Our research creates economic growth and jobs for Singapore, and enhances lives by improving societal outcomes in healthcare, urban living, and sustainability. A*STAR plays a key role in nurturing scientific talent and leaders for the wider research community and industry. A*STAR's R&D activities span biomedical sciences to physical sciences and engineering, with research entities primarily located in Biopolis and Fusionopolis. For ongoing news, visit About Diagnostics Development Hub (DxD Hub) The Diagnostics Development Hub is a national platform hosted by the Agency for Science, Technology and Research (A*STAR). DxD Hub aims to accelerate the transformation of innovations into clinically validated diagnostic devices that are ready for market adoption. Through impactful products, empowering local enterprises and anchoring global companies in Singapore, DxD Hub contributes to the development of an effective diagnostic devices' ecosystem in Singapore. For ongoing news, visit About MedTech Catapult MedTech Catapult (MC) is a national initiative designed to accelerate the product development and commercialisation of high-value life science instruments and regulated medical devices. MC partners with product owners, local contract manufacturers (CMs), and leverages external design houses, and other key stakeholders to guide innovations from concept to market. Their goal is to strengthen Singapore's medtech ecosystem by providing dedicated engineering, quality assurance, regulatory affairs, clinical affairs, project management and commercialisation support to derisk and support products towards commercialisation and market adoption whilst supporting pull-through to local manufacturing. View original content to download multimedia: SOURCE ClavystBio Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Globe and Mail
03-06-2025
- Business
- Globe and Mail
Renovaro Secures Key U.S. Patent to Strengthen AI-Driven Drug Discovery and Diagnostics Platform
Expanded IP Portfolio Enhances Data Harmonization and Predictive Analytics Capabilities for High-Growth Biomedical Markets LOS ANGELES, June 03, 2025 (GLOBE NEWSWIRE) -- Renovaro Inc. (NASDAQ: RENB), a clinical-stage precision medicine company, today announced that its subsidiary BioSymetrics has received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for a new patent application titled 'Methods, Systems, and Frameworks for Unbiased Data in Drug Discovery Predictions' (Application No. 18/058,752). This patent strengthens Renovaro's AI and machine learning intellectual property portfolio by protecting novel methods for integrating and harmonizing diverse biomedical data sources—such as genomics, electronic health records, imaging, and clinical trial data—into a standardized framework for predictive modeling. 'This patent is a strategic milestone for Renovaro,' said David Weinstein, CEO of Renovaro. 'Together with our previously granted patent, it forms the technological foundation of a scalable, end-to-end platform for AI-powered drug discovery and diagnostics and strengthens our position in the fast-growing market for data-driven therapeutics and clinical insights.' Key Drivers for Renovaro: Expands Foundational IP: Builds on core patent (US 11,379,757), granted in July 2022, which protects machine learning pipeline optimization through advanced feature selection and model tuning. Addresses Real-World Challenges: Tackles integration of siloed and heterogeneous data—an unmet need in pharmaceutical R&D and clinical practice. Enhances Commercial Potential: Enables scalable, distributed computing for biomedical analytics across use cases in rare disease, clinical trials, and personalized medicine. Supports Revenue Growth Strategy: Protects Renovaro's differentiated technology approach, critical for commercial partnerships, licensing opportunities, and platform deployment in life sciences and healthcare. The new patent introduces methods that operate across distributed and parallel computing environments, allowing for real-time, reproducible predictive analytics at scale. This infrastructure is vital as the biopharma industry increases reliance on AI to improve efficiency, reduce costs, and accelerate time-to-market for new therapies. This patent allowance reinforces Renovaro's commitment to building category-defining technology platforms that drive value for patients, partners, and shareholders alike. About Renovaro Inc. Renovaro aims to accelerate precision and personalized medicine for longevity powered by mutually reinforcing AI and biotechnology platforms for early diagnosis, better-targeted treatments, and drug discovery. Renovaro Inc. includes RenovaroBio with its advanced cell-gene immunotherapy company and RenovaroCube that is leveraging AI for multi-omic diagnostics and drug development, and BioSymetrics which specializes in contingent AI for precision neurology. For more information, visit Forward-Looking Statements This release contains forward-looking statements, including those relating to the pending litigation and the proposed merger. These statements involve risks and uncertainties and are subject to change based on future developments. Renovaro undertakes no obligation to update any forward-looking statements except as required by law. Investor Relations Chris Tyson Executive Vice President MZ Group - MZ North America 949-491-8235 RENB@ For media inquiries, please contact:
Yahoo
03-06-2025
- Business
- Yahoo
Why Apellis Pharmaceuticals, Inc. (APLS) Skyrocketed On Monday
We recently published a list of . In this article, we are going to take a look at where Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) stands against other top-performing stocks on Monday. Apellis Pharmaceuticals surged by 13.05 percent on Monday to finish at $19.14 apiece after earning a higher price target from an investment firm. On Monday, Wells Fargo raised its price target for the company to $29 from $26 previously, while maintaining an 'equal weight' rating for the stock. Wells Fargo said that the adjustment reflected its optimism about Apellis Pharmaceuticals, Inc.'s (NASDAQ:APLS) potential treatment for rare kidney diseases C3G and IC-MPGN, which could bolster opportunities for the company. A biomedical scientist in a lab coat conducting research on biopharmaceutical compounds. Wells Fargo expected the treatment to secure an approval, but underscored the need for a clearer understanding of its potential downside risks before becoming more optimistic on the stock. In the first quarter of the year, Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) widened its net loss by 39 percent to $92 million from $66 million in the same period last year. Revenues inched up by 3 percent to $166.8 million from $172.3 million year-on-year. READ NEXT: 20 Best AI Stocks To Buy Now and 30 Best Stocks to Buy Now According to Billionaires. Disclosure: None. This article is originally published at Insider Monkey.
Associated Press
27-05-2025
- Business
- Associated Press
John Snow Labs Acquires WiseCube to Refine and Safeguard Medical AI Models with Knowledge Graphs
LEWES, Del., May 27, 2025 (GLOBE NEWSWIRE) -- John Snow Labs, the AI for healthcare company, today announced the acquisition of WiseCube, a pioneer in biomedical knowledge graphs and AI-powered literature analysis. The acquisition strengthens the company's mission to deliver responsible, accurate, and explainable healthcare AI solutions enhanced by WiseCube's billion-scale knowledge platform. WiseCube unifies and analyzes disjointed biomedical datasets to provide fast, literature-backed answers to complex medical questions. Its integration of cutting-edge biomedical ontologies and documents ensures access to the most current and comprehensive medical knowledge. This capability has proven indispensable, uncovering new use cases and solutions John Snow Labs can support, such as drug discovery and precision medicine within the Medical Chatbot Platform. The WiseCube acquisition will enable John Snow Labs to: 'With John Snow Labs' leadership in healthcare AI, our combined teams can now bring safe and effective AI solutions to the market at scale,' said Vishnu Vettrivel, CEO, WiseCube. 'We look forward to improving research productivity, clinical decision-making, and patient outcomes together.' 'The integration of WiseCube's knowledge graph technology into our healthcare AI solutions enables a new level of accuracy and reliability for our customers,' said David Talby, CEO, John Snow Labs. 'We're excited to accelerate the ability to deliver real-world, production-ready solutions that clinicians and researchers can trust.' About John Snow Labs John Snow Labs, the AI for healthcare company, provides state-of-the-art software, models, and data to help healthcare and life science organizations put AI to good use. Developer of Medical LLMs, Healthcare NLP, Spark NLP, the Generative AI Lab No-Code Platform, and the Medical Chatbot, John Snow Labs' award-winning medical AI software powers the world's leading pharmaceuticals, academic medical centers, and health technology companies. Creator and host of The NLP Summit, the company is committed to further educating and advancing the global AI community. Contact Gina Devine Head of Communications John Snow Labs [email protected]
BreakingNews.ie
26-05-2025
- Science
- BreakingNews.ie
Scientists create soft robots able to walk out of the printers which made them
Scientists have created soft robots able to walk straight out of the machines which made them. The flexible, four-legged devices were developed using a new 3D printing system with an innovative method of upside-down printing. Advertisement Soft machines – made from compliant materials such as soft plastics – have huge potential for use in areas such as nuclear decommissioning, the biomedical sector and in space, researchers said. The soft robot is attached to air and then walks off the machine which made it (Maks Gepner/Edinburgh University/PA) A lack of scalable manufacturing and standardised design causes technical and financial barriers to the use of such devices, the scientists said. The Edinburgh University team from sought to overcome these challenges by developing a low-cost, desktop 3D printing system for creating soft robots. Their user-friendly setup can be assembled for under €500 using off-the-shelf parts. Advertisement The team demonstrated the capabilities of their new system by creating robots made from a soft plastic material and powered by air pressure. Once printed, the robots are connected to a compressed air supply before walking out of the machine on which they were made. The researchers believe this could pave the way for the use of intelligent soft robotic systems with no electronic parts. Lead engineer on the project, Maks Gepner, said: 'It used to take years to figure out how to print using these materials. Advertisement 'Using our new platform, anyone can now easily print things which were previously thought to be impossible. 'This is a game-changer for engineers and artists alike. 'Our hope is that this technology will help drive the next wave of research breakthroughs. 'Without the long-standing manufacturing and design bottlenecks holding it back, we believe soft robotics is ready to make a major real-world impact.' Advertisement Mr Gepner was supported on the project by fellow PhD student at the Centre for Doctoral Training in Robotics and Autonomous Systems, Jonah Mack, and lead academic Professor Adam A Stokes, head of the university's Institute for Bioengineering. World Thousands of humanoid robots take part in half mar... Read More Building and operating their new system – known as the Flex Printer – requires little prior knowledge, with first-time users able to assemble it and begin making robots in just a few days, the team said. They have made their designs publicly available to broaden access to soft robotic technologies and to help foster collaboration and improvements to the system. The findings are published in the journal Device. The research was funded by the Engineering and Physical Sciences Research Council. Advertisement
